Sunday, September 7, 2025

Curaleaf: The Analyst Take On The European Expansion

On April 7th, Curaleaf Holdings (CSE: CURA) announced that they completed $312 million acquisition of related party European company EMMAC Life Sciences, and subsequently they sold 31.5% of the company off to a single institutional investor for U$130 million. This money will be used to pay the $50 million cash tender while the rest of the cash will be used to fund Curaleaf international’s CAPEX through 2022.

Curaleaf currently has 14 analysts covering the company with a weighted 12-month price target of C$27.86. This is up from the average from last month of C$25.14. Four analysts have strong buy ratings and the other ten analysts have buy ratings. The street high comes from BTIG with a C$34 12-month price target and the lowest is C$24 from Cormark Securities.

Canaccord Genuity’s analyst, Matt Bottomley writes, “we believe the potential long-term optionality afforded by entrance into these geographies could be very attractive relative to its current purchase price, time while representing an international platform for potential M&A as these markets develop.” Bottomley believes that this $80 million will go towards the expansion into UK, Germany, Italy, Spain, and Portugal.

Bottomley makes a note that they believe Curaleafs $1.2 – $1.3 billion revenue and 30% EBITDA margin guided by management does not include 1) any contributions from EMMAC and 2) adult-use sales in New Jersey, which is included in their U$1.36 billion 2021 revenue estimate.

Meanwhile, Haywood’s analyst Neal Gilmer says, “The addition of EMMAC not only provides international exposure but positions the company to be a leader in the global cannabis market,” and adds that the strategic investment by a single investor gives legitimacy to the European market. Gilmer also adds that Curaleaf estimates that in 2020 the European medical cannabis market was $1 billion and is expected to >5x in the next three years.

Haywood gives three upcoming catalysts, which you can see below.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

ESGold Outlines $24.3 Million NPV For Tailings Reprocessing Project

First Majestic Encounters 711 g/t Silver Equivalent Over 8.0 Metres In Ongoing Exploration At Los Gatos

Related News

Adobe: “Results Were Actually Better Than Feared By Investors”

On March 22nd, Adobe Inc (NASDAQ: ADBE) reported its fiscal first quarter 2022 results. The...

Saturday, March 26, 2022, 03:10:00 PM

Osisko Gold: Haywood Upgrades Price Target From $19.75 to $22.25

Osisko Gold Royalties (TSX: OR) (NYSE: OR) provided an update on their deliveries received this...

Friday, July 10, 2020, 03:36:35 PM

Hut 8 Mining: Canaccord Halves Price Target To US$6.00

On May 12th, Hut 8 Mining (TSX: HUT) reported its first quarter financial results. The...

Tuesday, May 17, 2022, 04:06:00 PM

Peloton: BMO Says Q4 Leaves More Questions Than Answers

Peloton Interactive (Nasdaq: PTON) on Thursday announced its fiscal fourth-quarter financial results. The company announced...

Sunday, August 28, 2022, 05:18:00 AM

Galaxy Digital: BMO Cuts Price Target To $16 After Crypto Crash

On Monday, Galaxy Digital Holdings Ltd. (TSX: GLXY) reported its second quarter financial results. The...

Thursday, August 11, 2022, 11:36:00 AM